Effects of maintenance lithium treatment on serum parathyroid hormone and calcium levels: A retrospective longitudinal naturalistic study

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 1785-1791

  Albert, Umberto ^a   De Cori, David ^a   Aguglia, Andrea ^a   Barbaro, Francesca ^a   Lanfranco, Fabio ^b   Bogetto, Filippo ^a   Maina, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Bipolar disorder; Follow up study; Lithium side effects

Indexed keywords

CALCIUM; LITHIUM; PARATHYROID HORMONE;

ADULT; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BLOOD ANALYSIS; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MALE; PARATHYROID HORMONE BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 84937961482     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S86103     Document Type: Article

References (47)

1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 Suppl):S1–S50.
2. National Collaborating Centre for Mental Health (UK). Bipolar Dis­order: the Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. Leicester: National Institute for Health and Clinical Excellence; 2006.
3. Goodwin GM; Consensus Group of the British Association for Psychop­harmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition – recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346–388.
4. Grunze H, Kasper S, Goodwin G, Bowden C, Möller HJ; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry. 2004;5(3):120–135.
5. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Soci­eties of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10(2):85–116.
6. Yatham LN, Kennedy SH, O’Donovan C, et al; Canadian Network for Mood and Anxiety Treatments. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7 Suppl 3:S5–S69.
7. Yatham LN, Kennedy SH, O’Donovan C, et al; Guidelines Group, CANMAT. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8(6):721–739.
8. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guide­lines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225–255.
9. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.
10. Geddes JR, Goodwin GM, Rendell J, et al; BALANCE Investigators and Collaborators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385–395.
11. Malhi GS, Tanious M, Das P, Berk M. The science and practice of lithium therapy. Aust N Z J Psychiatry. 2012;46(3):192–211.
12. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721–728.
13. Albert U, De Cori D, Blengino G, Bogetto F, Maina G. [Lithium treat­ment and potential long-term side effects: a systematic review of the literature]. Riv Psichiatr. 2014;49(1):12–21.
14. Kallner G, Petterson U. Renal, thyroid and parathyroid function during lithium treatment: laboratory tests in 207 people treated for 1–30 years. Acta Psychiatr Scand. 1995;91(1):48–51.
15. Bendz H, Sjödin I, Toss G, Berglund K. Hyperparathyroidism and long-term lithium therapy – a cross-sectional study and the effect of lithium withdrawal. J Intern Med. 1996;240(6):357–365.
16. Kusalic M, Engelsmann F. Effect of lithium maintenance therapy on thyroid and parathyroid function. J Psychiatry Neurosci. 1999;24(3):227–233.
17. Albert U, De Cori D, Aguglia A, et al. Lithium-associated hyperpara­thyroidism and hypercalcaemia: a case-control cross-sectional study. J Affect Disord. 2013;151(2):786–790.
18. van Melick EJ, Wilting I, Ziere G, Kok RM, Egberts TC. The influence of lithium on calcium homeostasis in older patients in daily clinical practice. Int J Geriatr Psychiatry. 2014;29(6):594–601.
19. Oliveira TC, Campos Neto IA, Aguiar-Oliveira MH, Pereira Fde A. Evaluation of parathyroid function and mineral metabolism in psy­chiatric patients using lithium salts. Arq Bras Endocrinol Metabol. 2014;58(6):619–624.
20. Colt EW, Kimbrell D, Fieve RR. Renal impairment, hypercalcemia, and lithium therapy. Am J Psychiatry. 1981;138(1):106–108.
21. Toffaletti J, McComb RB, Bowers GN. Increase in dialyzable calcium associated with therapy with lithium. Clin Chem. 1979;25(10):1806–1809.
22. Nordenström J, Elvius M, Bågedahl-Strindlund M, Zhao B, Törring O. Biochemical hyperparathyroidism and bone mineral status in patients treated long-term with lithium. Metabolism. 1994;43(12):1563–1567.
23. Twigt BA, Houweling BM, Vriens MR, et al. Hypercalcemia in patients with bipolar disorder treated with lithium: a cross-sectional study. Int J Bipolar Disord. 2013;1:18.
24. Szalat A, Mazeh H, Freund HR. Lithium-associated hyperparathyroid­ism: report of four cases and review of the literature. Eur J Endocrinol. 2009;160(2):317–323.
25. Aronoff MS, Evens RG, Durell J. Effect of lithium salts on electrolyte metabolism. J Psychiat Res. 1971;8(2):139–159.
26. Nielsen JL, Christensen MS, Pedersen EB, Darling S, Amdisen A. Parathyroid hormone in serum during lithium therapy. Scand J Clin Lab Invest. 1977;37(4):369–372.
27. Christiansen C, Baastrup PC, Transbøl I. Development of ‘primary’ hyperparathyroidism during lithium therapy: longitudinal study. Neu­ropsychobiology. 1980;6(5):280–283.
28. Mak TW, Shek CC, Chow CC, Wing YK, Lee S. Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitu­dinal study. J Clin Endocrinol Metab. 1998;83(11):3857–3859.
29. Bilezikian JP, Khan AA, Potts JT; Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94(2):335–339.
30. American Psychiatric Association. Diagnostic and Statistic Manual of Mental Disorders. 4th ed. Text revised (DSM-IV-TR). Washington, DC: APA; 1994.
31. First MB, Spitzer RL, Gibbon M, Williams JBW, editors. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York (NY): Biometrics Research, New York State Psychiatric Institute; 2002.
32. Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-IV (SCID). NewYork State: Biometric Research; 1995.
33. Young R, Biggs J, Ziegler V, Meyer D. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429–435.
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psy­chiatry. 1960;23:56–62.
35. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55.
36. Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Admin­istration, 1976.
37. Ng F, Mammen OK, Wilting I, et al; International Society for Bipolar Disorders. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11(6):559–595.
38. Lally J, Lee B, McDonald C. Prevalence of hypercalcaemia in patients on maintenance lithium therapy monitored in primary care. Ir Med J. 2013;106(1):15–17.
39. Rej S, Segal M, Low NC, et al. In this correspondence, preliminary data in 100 lithium users found that urine osmolality correlated with chronic kidney disease, diabetes mellitus, and hypothyroidism. We hypothesize that GSK-3β inhibition is a potential mechanism for lithium-associated medical illness. Med Hypotheses. 2015;84(6):602.
40. Awad SS, Miskulin J, Thompson N. Parathyroid adenomas versus four-gland hyperplasia as the cause of primary hyperparathyroid­ism in patients with prolonged lithium therapy. World J Surg. 2003;27(4):486–488.
41. Haden ST, Stoll AL, McCormick S, Scott J, Fuleihan G el-H. Alterations in parathyroid dynamics in lithium-treated subjects. J Clin Endocrinol Metab. 1997;82(9):2844–2848.
42. Lienert D, Rege S. Moans, stones, groans, bones and psychiatric over­tones: lithium-induced hyperparathyroidism. Aust N Z J Psychiatry. 2008;42(2):171–173.
43. Díaz-Soto G, Julián MT, Puig-Domingo M. Normocalcemic primary hyperparathyroidism: a newly emerging disease needing therapeutic intervention. Hormones (Athens). 2012;11(4):390–396.
44. Lehmann SW, Lee J. Lithium-associated hypercalcemia and hyper­parathyroidism in the elderly: what do we know? J Affect Disord. 2013;146(2):151–157.
45. Werneke U, Ott M, Renberg ES, Taylor D, Stegmayr B. A decision analysis of long-term lithium treatment and the risk of renal failure. Acta Psychiatr Scand. 2012;126(3):186–197.
46. Shapiro HI, Davis KA. Hypercalcemia and “primary” hyperparathyroid­ism during lithium therapy. Am J Psychiatry. 2015;172(1):12–15.
47. Mallette LE, Eichhorn E. Effects of lithium carbonate on human calcium metabolism. Arch Intern Med. 1986;146(4):770–776.